Evofem Biosciences, Inc. (EVFM) stock
EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
$0.01−0.00 (-10.00%)
Close on Oct 19, 2026Market cap $865.23KP/E –Yield –
Evofem Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Evofem Biosciences's R&D Expenses for the twelve months ending Dec 31, 2024 was $1.85M. For fiscal 2024 it was $1.85M, down 37.2% from the year before. Over ten years it grew -9.8% a year on average. The highest annual figure on record is $43.42M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.85M | -37.2% |
| FY2023 | Dec 31, 2023 | $2.94M | -88.3% |
| FY2022 | Dec 31, 2022 | $25.03M | -24.4% |
| FY2021 | Dec 31, 2021 | $33.13M | +94.3% |
| FY2020 | Dec 31, 2020 | $17.05M | -23.3% |
| FY2019 | Dec 31, 2019 | $22.23M | -48.8% |
| FY2018 | Dec 31, 2018 | $43.42M | +84.4% |
| FY2017 | Dec 31, 2017 | $23.54M | +257.8% |
| FY2016 | Dec 31, 2016 | $6.58M | -80.9% |
| FY2015 | Dec 31, 2015 | $34.41M | +564.9% |
| FY2014 | Dec 31, 2014 | $5.17M | -54.8% |
| FY2013 | Dec 31, 2013 | $11.45M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $649.00K | +61.4% |
| Q3 FY2024 | Sep 30, 2024 | $332.00K | -38.5% |
| Q2 FY2024 | Jun 30, 2024 | $270.00K | -84.0% |
| Q1 FY2024 | Mar 31, 2024 | $594.00K | -88.6% |
| Q2 FY2023 | Jun 30, 2023 | $402.00K | -94.8% |
| Q1 FY2023 | Mar 31, 2023 | $540.00K | -94.8% |
| Q4 FY2022 | Dec 31, 2022 | $1.69M | -80.5% |
| Q3 FY2022 | Sep 30, 2022 | $5.21M | -40.2% |
| Q2 FY2022 | Jun 30, 2022 | $7.74M | -9.0% |
| Q1 FY2022 | Mar 31, 2022 | $10.39M | +43.1% |
| Q4 FY2021 | Dec 31, 2021 | $8.66M | +45.6% |
| Q3 FY2021 | Sep 30, 2021 | $8.70M | +106.3% |
| Q2 FY2021 | Jun 30, 2021 | $8.51M | +222.2% |
| Q1 FY2021 | Mar 31, 2021 | $7.26M | +71.0% |
| Q4 FY2020 | Dec 31, 2020 | $5.95M | +73.3% |
| Q3 FY2020 | Sep 30, 2020 | $4.22M | -25.5% |
| Q2 FY2020 | Jun 30, 2020 | $2.64M | -49.7% |
| Q1 FY2020 | Mar 31, 2020 | $4.25M | -46.2% |
| Q4 FY2019 | Dec 31, 2019 | $3.43M | -64.9% |
| Q3 FY2019 | Sep 30, 2019 | $5.66M | -42.5% |
| Q2 FY2019 | Jun 30, 2019 | $5.25M | -55.7% |
| Q1 FY2019 | Mar 31, 2019 | $7.89M | -34.0% |
| Q4 FY2018 | Dec 31, 2018 | $9.77M | -12.9% |
| Q3 FY2018 | Sep 30, 2018 | $9.85M | +57.3% |
| Q2 FY2018 | Jun 30, 2018 | $11.83M | +190.2% |
| Q1 FY2018 | Mar 31, 2018 | $11.96M | +503.4% |
| Q4 FY2017 | Dec 31, 2017 | $11.22M | +1112.2% |
| Q3 FY2017 | Sep 30, 2017 | $6.26M | +549.1% |
| Q2 FY2017 | Jun 30, 2017 | $4.08M | +185.5% |
| Q1 FY2017 | Mar 31, 2017 | $1.98M | – |
| Q4 FY2016 | Dec 31, 2016 | $925.25K | – |
| Q3 FY2016 | Sep 30, 2016 | $964.94K | – |
| Q2 FY2016 | Jun 30, 2016 | $1.43M | – |
See a number that looks wrong?